Advanced in Acute Myeloid Leukemia (AML)

Maria H. Gilleece

St James Institute Of Oncology
Leeds, ENG, GB 
Advanced in Acute Myeloid Leukemia (AML)
St James Institute Of Oncology
Leeds, ENG, GB 
OverviewLocationsClinical Research

Overview

Maria Gilleece practices in Leeds, United Kingdom. Ms. Gilleece is rated as an Advanced expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). Her top areas of expertise are Graft Versus Host Disease (GvHD), Vitamin D Deficiency, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Graft.

Her clinical research consists of co-authoring 43 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 15 articles and participated in 4 clinical trials in the study of Acute Myeloid Leukemia (AML).

Gender
Female

Locations

St James Institute of Oncology
Leeds, ENG, United Kingdom
Other Locations
Sheffield, ENG, United Kingdom
St George's Hospital and Medical School
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects With Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance After Allogeneic Haematopoietic Stem Cell Transplantation
A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects With Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance After Allogeneic Haematopoietic Stem Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: Azacitidine
Study Phase: Phase 3
A UK Multicentre Study of Haploidentical Stem Cell Transplantation in Patients With Haematological Malignancies
A UK Multicentre Study of Haploidentical Stem Cell Transplantation in Patients With Haematological Malignancies
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Procedure
Study Phase: Phase 2
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
Enrollment Status: Terminated
Publish Date: May 24, 2022
Intervention Type: Drug, Biological, Procedure
Study Drugs: ATIR101 Ex Vivo-Depleted T Lymphocyte-Enriched Leukocyte, Cyclophosphamide
Study Phase: Phase 3
Multicenter Randomized Phase II Study to Evaluate the Efficacy of Prophylactic Transfer of CD4 Lymphocytes After T-cell Depleted Reduced Intensity HLA-Identical Sibling Transplantation for Haematological Cancers
Multicenter Randomized Phase II Study to Evaluate the Efficacy of Prophylactic Transfer of CD4 Lymphocytes After T-cell Depleted Reduced Intensity HLA-Identical Sibling Transplantation for Haematological Cancers
Enrollment Status: Unknown
Publish Date: February 12, 2019
Intervention Type: Other
Study Drug: CD4 Donor Lymphocytes
Study Phase: Phase 2
View 3 Less Clinical Trials

43 Total Publications

Virus detection by short read high throughput sequencing in a high virus low cellular background.
Virus detection by short read high throughput sequencing in a high virus low cellular background.
Journal: NPJ vaccines
Published: December 24, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Gilleece's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile